Delgocitinib ointment is a topical Janus kinase (JAK) inhibitor primarily used for the treatment of atopic dermatitis and moderate to severe chronic hand eczema (CHE).

1、 Drug name

1. Common name: Digotinib

2. Product Name: Corectim

2、 Indications

Suitable for treating atopic dermatitis (アトピー dermatitis).

3、 Specifications and characteristics

1. Specifications:

Digotinib ointment 0.5%: contains 5mg of Digotinib per gram.

Digotinib ointment 0.25%: contains 2.5mg of Digotinib per gram.

2. Appearance: White ointment.

4、 Main components

1. Active ingredient: Digotinib.

2. Accessories: white Vaseline, paraffin, squalene.

5、 Usage and dosage

1. Adults: Usually use 0.5% ointment twice a day, apply an appropriate amount to the affected area. The maximum coating amount per time is 5g.

2. Children: Usually use 0.25% ointment twice a day, apply an appropriate amount to the affected area. According to the symptoms, 0.5% ointment can also be used twice a day. The maximum coating amount per time is 5g, which needs to be adjusted according to physical condition.

6、 Dose adjustment

1. If the symptoms do not improve within 4 weeks of treatment, the use should be stopped.

2. After the symptoms improve, it is necessary to evaluate whether medication needs to be continued and avoid long-term indiscriminate use.

3. Children's symptoms improve after using 0.5% ointment, and it may be considered to switch to 0.25% ointment.

7、 Medication precautions

1. Each application should not exceed 30% of the body surface area.

2. Avoid applying to mucous membranes, ulcers, and obvious erosions.

3. If it accidentally gets into the eyes, rinse immediately with clean water.

4. If there is a skin infection before treatment, avoid using it at the site of infection; If necessary, perform anti infective treatment first.

8、 Medication for special populations

1. Pregnant women: Use only when the benefits of treatment outweigh the risks. Animal experiments have shown that drugs can pass through the placenta.

2. Breastfeeding period: Treatment benefits and breastfeeding benefits should be considered when deciding whether to continue breastfeeding. Animal experiments have shown that drugs can enter breast milk.

3. Children: The safety and efficacy of infants under 6 months of age have not been established.

9、 Adverse reactions

1. Common (≥ 1%) adverse reactions include folliculitis at the application site, itching at the application site, erythema at the application site, irritation at the application site, and contact dermatitis.

2. Infection related: Herpes like eczema, oral herpes, herpes simplex, shingles, pustules, etc.

3. Other: Occasional Kaposi's varicella like rash.

10、 Contraindications

Patients with a history of allergies to any of the ingredients in this product are prohibited from using it.

11、 Drug interactions

1. Digotinib is a substrate for P-glycoprotein (P-gp), organic anion transporter 3 (OAT3), and organic cation transporter 2 (OCT2) (in vitro data).

2. It should be avoided to use drugs that are metabolized by CYP450 enzymes and have a narrow therapeutic window, and should be monitored carefully.

12、 Storage method

Please store in a cool place and avoid high temperatures. Please refer to the packaging instructions for specific storage conditions. The validity period is 36 months.

13、 Manufacturer

Torii Pharmaceutical Co., Ltd.

Delgocitinibinformation